General Information of Drug (ID: DMW9I1X)

Drug Name
4-Fluoren-9-ylidenemethyl-pyridine
Synonyms
MLS002694154; 4-(9H-fluoren-9-ylidenemethyl)pyridine; 4-Fluoren-9-ylidenemethyl-pyridine; NSC83319; AC1L5UM6; NCIOpen2_004593; Oprea1_438447; Oprea1_732020; BDBM8644; CHEMBL383145; 9-(4-pyridylmethylene)fluorene; SCHEMBL8276094; CTK7D1435; (4-Pyridylmethylene)fluorene 34; HMS3088F22; 4-(fluoren-9-ylidenemethyl)pyridine; ZINC13283063; NSC-83319; AKOS000634958; Pyridine, 4-(fluoren-9-ylidenemethyl)-; 4-(9H-Fluorene-9-ylidenemethyl)pyridine; SMR001560085; BAS 00004846; SR-01000321373
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 255.3
Topological Polar Surface Area (xlogp) 4.1
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 0
Hydrogen Bond Acceptor Count (hbondacc) 1
Chemical Identifiers
Formula
C19H13N
IUPAC Name
4-(fluoren-9-ylidenemethyl)pyridine
Canonical SMILES
C1=CC=C2C(=C1)C3=CC=CC=C3C2=CC4=CC=NC=C4
InChI
InChI=1S/C19H13N/c1-3-7-17-15(5-1)16-6-2-4-8-18(16)19(17)13-14-9-11-20-12-10-14/h1-13H
InChIKey
YVNXZDHQCSSQMR-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
256445
TTD ID
D04IJE

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Aromatase (CYP19A1) TTSZLWK CP19A_HUMAN Inhibitor [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 Synthesis and evaluation of (pyridylmethylene)tetrahydronaphthalenes/-indanes and structurally modified derivatives: potent and selective inhibitor... J Med Chem. 2005 Mar 10;48(5):1563-75.
2 Effective aromatase inhibition by anastrozole in a patient with gonadotropin-independent precocious puberty in McCune-Albright syndrome. J Pediatr Endocrinol Metab. 2002;15 Suppl 3:945-8.
3 Aromatase inhibitors--theoretical concept and present experiences in the treatment of endometriosis. Zentralbl Gynakol. 2003 Jul-Aug;125(7-8):247-51.
4 Aminoglutethimide-induced protein free radical formation on myeloperoxidase: a potential mechanism of agranulocytosis. Chem Res Toxicol. 2007 Jul;20(7):1038-45.
5 Enantioselective nonsteroidal aromatase inhibitors identified through a multidisciplinary medicinal chemistry approach. J Med Chem. 2005 Nov 17;48(23):7282-9.
6 Aromatase inhibitors for male infertility. J Urol. 2002 Feb;167(2 Pt 1):624-9.
7 Toremifene-atamestane; alone or in combination: predictions from the preclinical intratumoral aromatase model. J Steroid Biochem Mol Biol. 2008 Jan;108(1-2):1-7.
8 Pharmacophore modeling strategies for the development of novel nonsteroidal inhibitors of human aromatase (CYP19). Bioorg Med Chem Lett. 2010 May 15;20(10):3050-64.
9 Highly potent first examples of dual aromatase-steroid sulfatase inhibitors based on a biphenyl template. J Med Chem. 2010 Mar 11;53(5):2155-70.
10 Emerging drugs in neuropathic pain. Expert Opin Emerg Drugs. 2007 Mar;12(1):113-26.